Biontech Se | search
Click here to view Biontech Se news from 60+ newspapers.
Bookmark or Share- BioNTech | Our mission: basic research in mRNA technology and ...With decades of deep immunology expertise and experience in developing and optimizing mRNA as part of its broad suite of novel technologies, the company is working with the global community to defeat life-threatening and serious diseases such as cancer, COVID-19, malaria and tuberculosis.
- Welcome to our investor page | BioNTechBiopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
- BioNTech to Report First Quarter 2024 Financial Results andMAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024.
- BioNTech USBioNTech US originated as Neon Therapeutics, which was acquired by BioNTech SE in 2020 to combine neoantigen expertise in the field of cancer medicine and immunology by leveraging the highly complementary capabilities and resources of the two companies.
- BioNTechBioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49 6131 9084-0 F: +49 6131 9084-2121 M: ...
More
